Drugs /

phenformin

Back to Drugs List

Overview

NCI Definition [1]:
An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Phenformin is not used clinically due to the high risk of lactic acidosis that is associated with its use.

Clinical Trials

View Clinical Trials for phenformin

Phenformin has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating phenformin, 1 is phase 1 (1 open).

BRAF V600E and BRAF V600K are the most frequent biomarker inclusion criteria for phenformin clinical trials.

Melanoma is the most common disease being investigated in phenformin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Phenformin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating phenformin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
dbi, fenformin, phenformin, phenformine, phenethylbiguanide, phenforminum, fenformina, phenformin [chemical/ingredient], β-phenethybiguanide, imidodicarbonimidic diamide, n-(2-phenylethyl)-, phenformin (substance), phenformin, phenylethylbiguanide
NCIT ID [1]:
C81700
SNOMED ID [1]:
F-616D4

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.